T
Thomas Wessel
Researcher at Sunovion
Publications - Â 35
Citations - Â 1918
Thomas Wessel is an academic researcher from Sunovion. The author has contributed to research in topics: Eszopiclone & Mood disorders. The author has an hindex of 14, co-authored 35 publications receiving 1844 citations. Previous affiliations of Thomas Wessel include Sumitomo Chemical.
Papers
More filters
Journal ArticleDOI
Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder.
Maurizio Fava,W. Vaughn McCall,Andrew D. Krystal,Thomas Wessel,Robert Rubens,Judy Caron,David A. Amato,Thomas Roth +7 more
TL;DR: Eszopiclone/fluoxetine co-therapy was relatively well tolerated and associated with rapid, substantial, and sustained sleep improvement, a faster onset of antidepressant response on the basis of CGI, and a greater magnitude of the antidepressant effect.
Journal ArticleDOI
Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia.
Andrew D. Krystal,James K. Walsh,Eugene M. Laska,Judy Caron,David A. Amato,Thomas Wessel,Thomas Roth +6 more
TL;DR: Throughout 6 months, eszopiclone improved all of the components of insomnia as defined by DSM-IV, including patient ratings of daytime function, which is compelling evidence that long-term pharmacologic treatment of insomnia is efficacious.
Journal ArticleDOI
Nightly Treatment of Primary Insomnia With Eszopiclone for Six Months: Effect on Sleep, Quality of Life, and Work Limitations
James K. Walsh,Andrew D. Krystal,David A. Amato,Robert Rubens,Judy Caron,Thomas Wessel,Kendyl Schaefer,James M. Roach,Gene Wallenstein,Thomas Roth +9 more
TL;DR: This is the first placebo-controlled investigation to demonstrate that long-term nightly pharmacologic treatment of primary insomnia with any hypnotic enhanced quality of life, reduced work limitations, and reduced global insomnia severity, in addition to improving patient-reported sleep variables.
Journal ArticleDOI
An evaluation of the efficacy and safety of eszopiclone over 12 months in patients with chronic primary insomnia
TL;DR: Significant improvements in sleep and daytime function were evident in those switched from double-blind placebo to 6 months of open-label eszopiclone therapy and were sustained during the 6 years ofopen-label treatment for those receiving prior double- blind eszopylone.
Journal ArticleDOI
A 2-week efficacy and safety study of eszopiclone in elderly patients with primary insomnia.
Martin B. Scharf,Milton K. Erman,Russell Rosenberg,David Seiden,W. Vaughn McCall,David A. Amato,Thomas Wessel +6 more
TL;DR: Ezopiclone was well tolerated in elderly patients with primary insomnia, and the sleep efficacy was accompanied by significantly less napping and significantly higher ratings of daytime alertness, sense of physical well-being, and several quality-of-life parameters at the higher dose.